SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is trending due to its exceptionally active and dedicated community, which is relentlessly building a permissionless brand through various real-world products like Kendu Spice and Kendu Energy. Community members are emphasizing long-term conviction, strategic accumulation, and the project's expanding IRL presence across multiple blockchain networks.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust (SLV) is seeing extreme volatility, largely driven by the CME's repeated increases in silver margin requirements, which has fueled sharp sell-offs and liquidations. The community remains fiercely divided, with many bulls actively buying dips and anticipating a massive short squeeze to much higher prices due to underlying industrial demand and impending Chinese export restrictions, while bears warn of a classic pump-and-dump scheme and expect a steep correction. The ongoing debate highlights the tension between paper market dynamics and perceived tightening physical supply.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending on a powerful AI-driven surge, with skyrocketing demand for High Bandwidth Memory (HBM) leading to its entire 2026 HBM capacity being sold out. The community is buzzing with bullish sentiment, fueled by strong guidance and analyst upgrades, as the market re-evaluates its growth potential in the critical AI infrastructure sector despite some calls for caution due to its recent parabolic run.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following its long-awaited FDA approval of NEREUS (tradipitant) for motion sickness, marking the first new drug in this class in decades. Community discussions are highly focused on the drug's potential as a non-drowsy alternative and, crucially, its broader application to combat GLP-1 induced nausea, sparking significant speculation about potential buyout interest from major pharma players. Investors are actively debating immediate price action and anticipating further regulatory catalysts ahead.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is actively trending due to significant demand for its AI chips, highlighted by a substantial ByteDance order for H200s for 2026 and strategic moves like the rumored acquisition of AI21 Labs and integration of Groq's LPU technology. The community is buzzing about these developments, viewing them as solidifying Nvidia's leadership in the evolving AI landscape, particularly in countering competitors and capturing future inference workloads, despite ongoing discussions about market dynamics and geopolitical factors.

Threshold is a project merged from the NuCypher and Keep networks, which strives to provide different threshold cryptography solutions in a fully decentralized manner to the web3 community. Threshold cryptography is a technology that uses cryptography to unlock greater utility and usability for digital assets without needing to trust a centralized party. Threshold cryptography distributes sensitive operations across multiple independent entities – like nodes in a network – and requires a threshold, or minimum number of those entities to cooperate for the operation to be successful.

Threshold Network Token

Threshold Network Token ($T) is drawing significant attention, driven by community excitement around its role in decentralized Bitcoin (tBTC) and its perceived potential to replace existing wrapped Bitcoin solutions. Traders are actively discussing increasing trading volume and its utility as a crucial bridge between major crypto ecosystems.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart (UPST) is experiencing highly polarized sentiment, with a vocal community anticipating a significant short squeeze driven by its substantial short interest, while others remain extremely bearish. Discussions are heavily centered on how potential interest rate shifts and anticipated announcements regarding balance sheet funding or new partnerships will impact its AI lending model. This volatility-prone fintech stock sees active debate among traders over market maker influence and long-term investors weighing its growth prospects against past market underperformance.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is actively discussed as key semiconductor companies are reportedly involved in significant AI-related investments and acquisitions, influencing broader tech sector sentiment. Community perspectives are divided, with many anticipating continued gains from the AI trade while others express caution regarding a potential 'AI Bubble' amid evolving economic data and geopolitical factors affecting global chip supply.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root (NASDAQ: ROOT) is currently trending as community discussion highlights a stark contrast between its reported Q3 fundamental improvements and recent stock performance. While bulls point to a decisive shift towards profitability, record policies in force, enhanced telematics, and growing partnerships as evidence of deep undervaluation, they also decry extreme price volatility and perceived market manipulation. Skeptics, however, question the company's scalability and management's communication, maintaining a cautious outlook despite expectations for an "explosive" Q4.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending due to widespread anticipation of a major announcement concerning its 100-qubit chiplet-based quantum system, alongside speculation about potential partnerships at the upcoming CES event. The community is sharply divided, with bulls anticipating a significant rally, while bears cite insider selling, prior milestone delays, and a high valuation for the early-stage quantum company. This intense debate underscores the speculative nature of the sector, with investors closely watching for definitive progress to validate its ambitious roadmap.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Nutriband’s shareholders will retain a 10% shareholding in Earth Vision Bio.</li><li>The firm will use the proceeds from the sale of Pocono Pharma to continue developing AVERSA Fentanyl.</li><li>It expects annual U.S. sales from AVERSA Fentanyl to reach $80 million to $200 million.</li></ul>Shares of Nutriband Inc. (<a href="https://stocktwits.com/symbol/NTRB">NTRB</a>) surged more than 18% on Monday after the company announced an agreement to sell 90% stake in its subsidiary, Pocono Pharmaceutical, to EarthVision Bio for $5 million.Nutriband’s shareholders will retain a 10% shareholding in Earth Vision Bio following the acquisition, it stated.Nutriband will use the proceeds from the sale of Pocono Pharma towards its continued development of AVERSA Fentanyl. The company develops transdermal drug delivery systems that are focused on preventing abuse and misuse of medications like opioids using its proprietary AVERSA Technology.<h2 class="st-heading-2">Bet On Abuse-Deterrent Aversa Fentanyl</h2>The U.S. government has been cracking down on illicit fentanyl. U.S. President Donald Trump earlier this month signed an executive order designating it as a weapon of mass destruction and recognizing the substance as a direct threat to U.S. national security.Nutriband’s AVERSA Fentanyl uses its abuse-deterrent technology, which is designed to improve the safety profile of transdermal drugs that are susceptible to abuse, such as fentanyl, while making sure these drugs remain accessible to patients who need them.Nutriband has been partnering with Kindeva Drug Delivery to develop AVERSA Fentanyl, which combines Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch. It expects annual U.S. sales from AVERSA Fentanyl to reach $80 million to $200 million.Nutriband had signed a non-binding Letter of Intent (LOI) with Qvanta Group of Companies to explore potential collaboration areas, including secure AI and analytics platforms for regulated pharmaceutical data, and cybersecurity that support abuse-deterrent technologies.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around NTRB trended in “extremely bullish” territory amid “high” message volumes.&nbsp;<figure class="image"><img style="aspect-ratio:639/68;" src="https://news.stocktwits-cdn.com/ntrb_PNG_d487765902.webp" alt="Retail sentiment around NTRB trended in “extremely bullish” territory amid “high” message volumes. " width="639" height="68"></figure>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena. (Photo by Sarah Reingewirtz/MediaNews Group/Los Angeles Daily News via Getty Images)

What’s Driving Nutriband Shares Higher Today?

Nutriband has agreed to sell 90% of its stake in its subsidiary Pocono Pharmaceuticals for $5 million. 

Equity

Nutriband has agreed to sell 90% of its stake in its subsidiary Pocono Pharmaceuticals for $5 million. 


<ul class="summary-bullets"><li>Following the written FDA response, the company believes there is alignment with the agency on the proposed patient population for enrollment in its registration trial.</li><li>The company also plans to pursue another follow-up meeting to finalize details on the next clinical trial design that were not fully resolved in the written response. &nbsp;</li><li>Galectin Therapeutics also secured a $10 million line of credit from its chairman that would cover its expenditures until at least March 2027.</li></ul>Galectin Therapeutics Inc. (<a href="https://stocktwits.com/symbol/GALT">GALT</a>) shares plunged more than 30% in Friday morning trading after the company announced it had received feedback from the U.S. Food and Drug Administration (FDA) on its belapectin drug. The pharma company also announced a new $10 million line of credit.The company said that the FDA provided a written response to its Type C meeting—a non-urgent, non-milestone meeting—request regarding the development of belapectin, its investigational galectin-3 inhibitor for patients with MASH cirrhosis and portal hypertension.The FDA feedback has led Galectin Therapeutics to believe that there is alignment with the agency on the patient population proposed for enrollment in a registration trial.Separately, the company announced that its chairman, Richard E. Uihlein, will provide a $10 million unsecured, convertible line of credit financing.<h2 class="st-heading-2">FDA Clarification</h2>Galectin Therapeutics had requested an in-person or teleconference meeting with the FDA to address its queries regarding the development of belapectin. However, the FDA converted its initial request for a meeting to a written response.The company now plans to pursue another follow-up Type C meeting to finalize details on the next clinical trial design that were not fully resolved in the written response, it said. &nbsp;Galectin Therapeutics believes the meeting will provide an opportunity to clarify recent biomarker data that were not added to the initial submission ,and said that the next FDA interaction would be important to gain full clarity to advance belapectin towards the next Phase 3 clinical trial.<h2 class="st-heading-2">Line Of Credit</h2>The $10 million unsecured, convertible line of credit from the company’s chairman, along with its cash reserves, would fund Galectin Therapeutics’ expenditures until at least March 2027, it said. The maturity dates of all convertible lines of credit and convertible notes payable to its chairman have been extended through June 30, 2027.“This additional financing will enable us to continue to explore multiple strategies for the advancement of belapectin. We will provide updates as they become available,” Joel Lewis, Chief Executive Officer at Galectin Therapeutics, said.“Our focus remains on advancing belapectin for patients with MASH cirrhosis and portal hypertension,” he added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around Galectin Therapeutics remained in the ‘bullish’ territory over the past 24 hours, and message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1263/161;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_19_at_8_42_09_PM_png_3dac2150a5.webp" alt="On Stocktwits, the retail sentiment around Galectin Therapeutics remained in the ‘bullish’ territory over the past 24 hours, and message volume stayed at ‘high’ levels." width="1263" height="161"></figure>GALT was among the top trending tickers on Stocktwits at the time of writing.One user highlighted their bullish stance on GALT stock, stating that more clarity would come after the in-person FDA meeting.<stembedurl>https://stocktwits.com/skylightmoon/message/639688546</stembedurl>Shares of GALT are up over 263% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did GALT Shares Plummet Over 30% Today?

Galectin Therapeutics said it had received feedback from the FDA on its belapectin drug and also announced a new $10 million line of credit. 

<ul class="summary-bullets"><li>FueCell's fourth-quarter earnings received a boost from strong demand for electricity amidst the global AI push.</li><li>The company’s fourth-quarter revenue surged past estimates.</li><li>It reported a narrower loss in the quarter compared to the year-ago period.</li></ul>FuelCell Energy (<a href="https://stocktwits.com/symbol/FCEL">FCEL</a>) shares jumped 35% at the opening bell on Thursday after its fourth quarter revenue surged past analyst estimates, helped by increasing demand for electricity and data center projects amidst a global AI push, while its loss came in narrower than expected.&nbsp;As corporations and governments continue to adopt and implement artificial intelligence in their daily operations, the demand for data centers and electricity to keep them running has remained high, helping firms like FuelCell, which provide fuel cell power plants that generate clean electricity for businesses and communities.<h2 class="st-heading-2">&nbsp; Q4 Report</h2>The company reported fourth-quarter (Q4) revenue of $55 million, well above analyst estimates of $47.2 million, according to data from Fiscal.ai.&nbsp;“We believe that our fourth quarter performance and ongoing cost reductions have positioned us well to meet the accelerating demand for electricity and data center projects in the U.S. and internationally,” said Jason Few, President and CEO of FuelCell Energy.The company also posted an adjusted net loss attributable to common stockholders of $29.8 million in the quarter, compared to an adjusted net loss of $35.3 million in the fourth quarter of fiscal 2024. It reported an adjusted net loss per share of $0.83 compared to analysts’ expectation of a loss of $1.09 per share.&nbsp;<h2 class="st-heading-2"> How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around FCEL remained in ‘extremely bullish’ territory, and message volume remained ‘extremely high’. The stock is among the top 10 trending tickers on Stocktwits.&nbsp;<figure class="image"><img style="aspect-ratio:636/76;" src="https://news.stocktwits-cdn.com/Capture_3_PNG_f220001d6f.webp" alt="On Stocktwits, the retail sentiment around FCEL remained in ‘extremely bullish’ territory, and message volume remained ‘extremely high’. " width="636" height="76"></figure>One of the users on Stocktwits sounded “super bullish” on the stock after its earnings report.<figure class="image"><img style="aspect-ratio:648/109;" src="https://news.stocktwits-cdn.com/Capture2_PNG_cf56df1028.webp" alt="One of the users on Stocktwits sounded “super bullish” on the stock after FuelCell's earnings report." width="648" height="109"></figure>FuelCell Energy shares have declined nearly 24% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp; &nbsp;

In this photo illustration, the FuelCell Energy logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did FuelCell Stock Rocket 35% Today?

The company reported fourth-quarter revenue of $55 million, well above analyst estimates of $47.2 million, according to data from Fiscal.ai. 

<ul class="summary-bullets"><li>AXIL’s hearing products will hit over 3,700 Walmart stores, marking its largest single retail placement ever.&nbsp;</li><li>AXIL already has partnerships with Costco’s 300-plus retail and online stores.&nbsp;</li><li>Shares of AXIL are up over 30% in the last year.&nbsp;</li></ul>AXIL Brands, Inc. (AXIL) shares soared in Thursday’s premarket trade after the company announced a national retail distribution agreement with Walmart, which will bring its hearing protection and enhancement products to a massive new audience.The company said that under the agreement, AXIL's products, including its new AXIL® X30 LT earplugs, would be available in over 3,700 Walmart stores.&nbsp;According to the statement, the Walmart rollout represents the firm’s largest single retail placement to date.Shares of AXIL soared over 150% on the announcement.&nbsp;<h2 class="st-heading-2">New Horizons</h2>AXIL’s debut at Walmart is slated for February 2026, with the launch of a new product, the AXIL® X30 LT in-ear hearing protection plugs, available in retail outlets.In September this year, AXIL&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://goaxil.com/blogs/press-releases/axil-brands-launches-nationwide-at-costco-with-axil-xcor-se-advanced-hearing-protection-and-enhancement-earbuds">partnered with Costco</a> to take its earbuds to over 300 stores in the U.S. and eventually expanded to offer them on Costco’s online platform as well.&nbsp;Between Walmart and Costco placements, Axil’s expansion gives it access to millions of American consumers. In the latest statement, the company said that these partnerships position it for faster growth and greater brand visibility starting in 2026.“This partnership is a testament to the performance, value, and consumer demand for our products and will make our best-in-class hearing protection and enhancement technology available to millions of consumers who shop at Walmart every day,” Jeff Toghraie, Chairman and CEO at AXIL Brands, said.&nbsp;In October, <a href="https://stocktwits.com/symbol/AXIL">AXIL</a> announced its first-quarter (Q1) 2026 results, reporting a 17.2% increase in quarterly sales and an improvement in operating income of $0.4 million, compared to an operating loss in the same period last year.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AXIL jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped to ‘extremely high’ levels at the time of writing.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_11_at_5_03_15_PM_png_87987f7875.webp" alt="Screenshot 2025-12-11 at 5.03.15 PM.png">One user stressed their bullish outlook on the stock.&nbsp;<stembedurl>https://stocktwits.com/nader_1/message/638834530</stembedurl>Shares of AXIL are up over 30% in the last year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

The exterior of a Walmart store in Hollywood, Florida. (Photo by Joe Raedle/Getty Images)

 AXIL Stock Just Rocketed Over 150% Today — What’s The Walmart Angle? 

AXIL Brands announced a partnership with Walmart that would bring its products to the stores of America’s largest retailer.

<ul class="summary-bullets"><li>SENTI-202, the immune cell therapy cancer treatment, received a Regenerative Medicine Advanced Therapy (RMAT) designation that would make it eligible for quicker reviews.</li><li>This is the second FDA designation for the treatment this year.&nbsp;</li><li>On Stocktwits, retail sentiment for the stock rose to ‘extremely bullish’ territory while message volume jumped to ‘extremely high’ levels at the time of writing. &nbsp;</li></ul>Shares of Senti Biosciences, Inc. (SNTI) surged over 20% on Tuesday’s premarket trading after the company announced positive news around its cancer treatment.&nbsp;The clinical-stage biotech company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.sentibio.com/news-releases/news-release-details/senti-bio-announces-updated-senti-202-clinical-data-ongoing">announced</a> in a press release that the U.S. Food and Drug Administration (FDA) gave SENTI-202, an immune cell therapy cancer treatment, a Regenerative Medicine Advanced Therapy (RMAT) designation.&nbsp;<h2 class="st-heading-2">What Does This Mean?</h2>The RMAT designation from the FDA for the company’s cancer treatment indicates an expedited development and review, providing benefits similar to the FDA’s Breakthrough Therapy and the Fast Track programs such as higher interactions with the Agency through the development process as well as eligibility for quicker and even priority reviews.“This significant FDA designation validates both the tremendous need for better treatments for R/R AML and the promise of SENTI-202 to transform the therapeutic landscape for this notoriously aggressive cancer,” said Timothy Lu, Co-Founder and CEO of Senti Biosciences, in the press release. “We are incredibly pleased with the exciting clinical progress we recently shared at the ASH conference on SENTI-202.”Data from its ongoing trial showed a 50% overall response rate and 42% complete remission at the recommended Phase 2 dose, the company revealed. Earlier this year, the U.S. FDA granted the treatment Orphan Drug Designation.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/SNTI">SNTI</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1284/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_09_at_7_13_22_PM_png_c037e194c0.webp" alt="On Stocktwits, retail sentiment around&nbsp;SNTI jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels." width="1284" height="149"></figure>One user on the platform predicted that STNI’s share price could go up to $5. The stock was trading around $2.85 at the time of writing.&nbsp;<stembedurl>https://stocktwits.com/Stratsys/message/638587949</stembedurl>Shares of SNTI have fallen over 37% year to date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a medicine pill is seen in a hand dressed in a medical glove with the U.S. FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) 

SNTI Shares Surge Over 20% In Pre-Market Trade After FDA RMAT Designation For Cancer Treatment

Senti Biopharma shares rallied in premarket trading on Tuesday after its cancer treatment received a positive designation from the U.S. FDA.

SNTI Shares Surge Over 20% In Pre-Market Trade After FDA RMAT Designation For Cancer Treatment 

<ul class="summary-bullets"><li>Roth Capital sees potential FDA clearance for the software.</li><li>The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, the analyst said.&nbsp;</li><li>HeartBeam is now evaluating launching its 3D ECG system, which received FDA clearance in December 2024.</li></ul>Shares of HeartBeam, Inc. (BEAT) slumped 58% on Friday afternoon after the company said that the U.S. Food and Drug Administration refused clearance for its 12-Lead Electrocardiogram (ECG) Synthesis Software for arrhythmia assessment.The medical technology company said that it received a ‘not substantially equivalent’ letter from the FDA. A "Not Substantially Equivalent" (NSE) letter is an official notification from the FDA stating that a new medical device is not considered substantially equivalent to a legally marketed predicate device.The company said that it will be working with the agency to get to a resolution and expressed confidence in its clinical data. Earlier this month, HeartBeam had touted FDA clearance for the software as a major inflection point for the company.The company is now evaluating launching its 3D ECG system which received FDA clearance in December 2024.<h2 class="st-heading-2">Analyst Takeaway</h2>Roth Capital, however, sees potential FDA clearance for the software. The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, it said.While resolving the pathway for the 12-lead ECG synthesis software, management may decide to roll out the foundational 3D ECG system to concierge medical practices, preventive cardiology clinics, and hospital-at-home programs, the analyst said, as per The Fly.The analyst kept a ‘Buy’ rating on HeartBeam with a $4 price target. The price target represents a potential upside of over 138% from the stock’s closing price on Thursday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BEAT">BEAT stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user echoed Roth Capital’s opinion and said that the stock would beat $5 on FDA approval.<stembedurl>https://stocktwits.com/jamestocklover/message/637108009</stembedurl>Another noted that an NSE letter is not the end.<stembedurl>https://stocktwits.com/Rolltide2020/message/637103348</stembedurl>BEAT stock is down by 70% this year and by about 75% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/will-scot-stock-surges-after-baird-upgrade-analyst-calls-q3-a-watershed-quarter/cLPMv4RREfb">WillScot Stock Surges After Baird Upgrade – Analyst Calls Q3 A ‘Watershed Quarter’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

HeartBeam Stock Slumps After FDA Refuses Clearance For ECG Software

The company said it will work with the agency to reach a resolution and expressed confidence in its clinical data.

<ul><li>According to Telomir, more than 60,000 new cases of Leukemia are diagnosed each year in the U.S.</li><li>Leukemia cells rely heavily on iron as a fuel source, and Telomir-1 in previous research demonstrated the ability to reduce intracellular iron levels.&nbsp;</li><li>The new findings expand on the experimental drug’s previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models.</li></ul>Telomir Pharmaceuticals, Inc. (TELO) said on Friday that its investigational compound Telomir-1 killed aggressive human leukemia (HL60) cells in an in-vitro study.HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.Leukemia is a cancer of the blood and bone marrow defined by the uncontrolled growth of abnormal white blood cells.<a href="https://stocktwits.com/symbol/TELO">TELO shares</a> rose 8% at the time of writing.<h2 class="st-heading-2">New Findings</h2>According to Telomir, more than 60,000 new cases of Leukemia are diagnosed each year in the U.S. Leukemia cells rely heavily on iron as a fuel source, and Telomir-1 in previous research demonstrated the ability to reduce intracellular iron levels."The potency observed in HL60 leukemia cells is consistent with the broader biological patterns we have seen throughout Telomir's research…These findings support our scientific framework for evaluating Telomir-1 and inform the ongoing advancement of our overall oncology research program," the company’s chief scientific advisor, Itzchak Angel,<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://telomirpharma.com/#"> said</a>.The new findings expand on the experimental drug’s previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. The compound is the company’s lead candidate.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TELO jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume levels rose from ‘extremely low’ to ‘high’ levels.TELO stock is down 66% this year and by 69% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/google-ai-infra-chief-must-double-ai-compute-twice-a-year/cLPMFWiREOK">Google AI Infra Chief Says It Must Double AI Compute Twice A Year To Meet Demand: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Telomir Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death 

HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.

<ul class="summary-bullets"><li>Matt Kinsella said that computing is not the only product coming from quantum technologies.</li><li>There's a&nbsp;wide range of other products, including quantum sensors, quantum clocks, RF antennas, gravimeters, and&nbsp;different types of inertial sensing equipment.</li><li>Citing McKinsey’s research, the executive said Infleqtion’s total addressable market (TAM) is about $160 billion.</li></ul>Quantum computing company Infleqtion is set to go public via a Special Purpose Acquisition Company (SPAC) deal with Churchill Capital Corp. (CCCX), a blank-check company founded by ex-Citi executive Michael Klein. The ongoing government shutdown may have pushed back the going-public timeline slightly.&nbsp;Still, it hasn’t dampened Infleqtion CEO Matt Kinsella's optimism&nbsp;about&nbsp;what the future holds out for the company.Since the SPAC deal was announced, <a href="https://stocktwits.com/symbol/CCCX">Churchill Capital stock</a> has gained about 60%.Stockwits sat down with Kinsella, a former venture capitalist and a breakthrough technology evangelist, for a freewheeling chat about Inflqeqtion and its way forward:Here are excerpts from the interview:<h2 class="st-heading-2">Quantum Tech Is Much More Than Computing</h2>Kinsella attributed the skepticism toward the quantum computing industry to&nbsp;the pushed-out timelines. “For the last 20 years, it's always kind of been, oh, in five years we'll have quantum computing. It's always been this kind of rolling five years, and when you get there, it's five years from now we'll have it, and then five years from now you'll have it,” he said.The skepticism, according to the executive, stems from a bucket of misconceptions — that computing is the only product&nbsp;emerging from&nbsp;quantum technologies. “There's a whole umbrella of other types of products, such as quantum sensors, where quantum is already developing products that are truly orders of magnitude better than classical standards.” He also mentioned products such as quantum clocks, RF antennas, gravimeters, and other types of inertial sensing equipment.<h2 class="st-heading-2">Quantum Space In An Excited State</h2>Quantum computing stocks began the year on a slow note as they digested the torrid gains made in 2024, most of which occurred late in the year. These stocks also moved in tandem with the broader market when it declined sharply in early April, following President Donald Trump's announcement of punitive tariffs.&nbsp;Rumors that the Trump administration was eyeing stakes in quantum companies provided a solid boost to these stocks in October. D-Wave Quantum is among the best-performing publicly listed quantum companies this year,&nbsp;with gains exceeding 175%.<img src="https://news.stocktwits-cdn.com/QC_Stocks_Price_Gains_png_8e6c1e3da2.webp" alt="QC Stocks Price Gains.png">Source: KoyfinCitron Research touted in early October that Infleqtion is a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-spac-churchill-capital-s-stock-is-jumping-premarket-today/ch6EfqhR3Ln">far better quantum play&nbsp;</a>than Rigetti.Big Tech companies have also made significant inroads in quantum computing, with Alphabet announcing its Willow quantum chip late last year. Last month, it unveiled a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-tips-hat-to-sundar-pichai-for-google-s-latest-quantum-leap/cLG49mqR3Ag">breakthrough quantum algorithm,</a> dubbed “Quantum Echoes,”&nbsp;which CEO Sundar Pichai&nbsp;claims is 13,000 times faster than the best classical algorithm on one of the world's fastest supercomputers.&nbsp;That earned adulation even from Tesla CEO Elon Musk, who replied, “Looks like quantum computing is becoming relevant.”&nbsp;On Wednesday, IBM unveiled IBM Quantum Nighthawk, its most advanced quantum processor yet. As the industry makes slow and steady progress toward large-scale commercial adoption, Infleqtion finds itself in the sweet spot, positioning itself as a provider of a broad array of quantum products.<h2 class="st-heading-2">The Qubit Conundrum</h2>Kinsella said another misconception is a lack of understanding of the concept of logical qubits.&nbsp;A qubit&nbsp;is the basic unit of information in quantum computing, analogous to a bit in classical computing.He said Infleqtion holds the record for commercial qubits at 1600. “These are physical qubits, but what really matters in quantum computing are logical qubits. And logical qubits are error-corrected physical qubits.”“And it's generally thought that at 100 logical qubits, we will start to be able to do things with quantum computers that classical computers can't do.”Kinsella conceded that in terms of quantum computing, “we are not yet there.” While companies have different roadmaps for their logical qubits, Infleqtion plans to have 100 logical qubits by 2028. “So I think that's a reasonable line in the sand to say we'll start to do things that are commercially useful with quantum computers.”<h2 class="st-heading-2">Trump’s Quantum Thrust</h2>To a question about the Trump administration’s rumored interest in taking stakes in quantum computing companies, just as it invested in rare earth companies, Kinsella said such a move is possible. “I think it's the mentality of this administration to have taxpayers benefit from work that the government does with various deep tech companies.”Kinsella said the U.S. government is Infleqtion’s biggest customer and the company is constantly in talks with the government. “The topic of equity is brought up from time to time, and so I think, you know, we will continue to do a lot of business with the U.S. government, and those conversations will play out as they play out.”<h2 class="st-heading-2">China Competition</h2>It’s a race with China, just like it is in other areas. Kinsella said China is investing significantly more dollars in quantum than the U.S. has historically, but the U.S., along with its allies, invests more than China does. “But importantly, I think the U.S. is doing what it does often, and that's relying on its private capital markets to fund the innovation.”<h2 class="st-heading-2">Biggest Customer</h2>Kinsella said government accounts for more than 50% of Infleqtion’s revenue, with the Department of Defense (DoD) and government-run energy grids included in this category. The&nbsp;company also sells its clocks to non-governmental customers and academic institutions.Citing McKinsey’s research, the executive stated that Infleqtion’s total addressable market (TAM) is approximately $160 billion, comprising $30 billion in quantum sensing revenue and $130 billion in quantum computing revenue.&nbsp;<h2 class="st-heading-2">Consolidation In the Offing?</h2>While hinting that quantum computing is not a zero-sum game, Kinsella sees some degree of consolidation. “I think you'll probably end up with a handful of very large, very important quantum companies over the course of the next five to 10 years.”“One of the reasons why&nbsp;Infleqtion is going public is because I think we will be one of those consolidators, and we'll be one of those important companies. I think we have a head start now and an advantage, and we want to compound that advantage going forward.”<h2 class="st-heading-2">Government Shutdown Throws A Wrench</h2>Kinsella said Infleqtion was shooting for the end-of-the-year listing timeframe. “I hadn't really factored in the government shutdown into my calculations, and so I think it'll probably be in Q1, assuming the government gets reopened. Is it January or March? I don't know at this point.” The executive noted that the company has filed the S4 report confidentially with the SEC.<h2 class="st-heading-2">Message For Retail Investors</h2>“I personally believe quantum is going to be a very important technological shift for humanity over the course of the next decade. And I think it's great that the retail investing community is going to have more options to be able to participate in that over time,”&nbsp;Kinsella said, urging retail investors to do their due diligence. “But I think it's great that there will be the opportunity to invest in, you know, now another quantum company like Infleqtion.”“If you want to have exposure to the broad spectrum of opportunities that quantum can provide across both sensing and computing, Infleqtion is a very good way to represent that broader quantum bet.”Infleqtion will be the only publicly traded neutral-atom quantum, he said.&nbsp;That means it’s a company&nbsp;that develops quantum computers using neutral atoms, which&nbsp;lack an electrical charge. These companies use lasers to trap and manipulate these neutral atoms, arranging them into precise configurations to act as qubits for complex calculations.Kinsella thinks “neutral atoms are going to be the ones that win in quantum computing and therefore, we would be the way to express that.”For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/intel-hit-by-ai-brain-drain-as-top-execs-depart-for-rivals/cLPdQ7DRE2w">&nbsp;Intel Hit By AI Brain Drain As Top Execs Depart For Rivals: Sachin Katti Joins OpenAI After Saurabh Kulkarni's Jump To AMD</a>

 Citron Research touted in early October that Infleqtion is a far better quantum play than Rigetti.

EXCLUSIVE: Quantum Stocks Are Still Hot — And Infleqtion's CEO Sees Industry Consolidation, $160B Opportunity As It Heads For SPAC Listing

Quantum computing company Infleqtion is set to go public via a Special Purpose Acquisition Company (SPAC) deal with Churchill Capital Corp. 

Quantum Stocks Are Still Hot — And Infleqtion's CEO Sees Industry Consolidation, $160B Opportunity As It Heads For SPAC Listing

Matt Kinsella says quantum technology will be a major technological shift for humanity over the next decade.


<ul class="summary-bullets"><li>CEO Kevin McAleenan said, with the Ask Sage deal, BigBear is creating a secure, integrated AI platform that connects software, data, and mission services in one place.</li><li>The deal is expected to close in either the fourth quarter or the first quarter of next year.</li><li>Despite the ongoing government shutdown, the company reaffirmed its 2025 revenue guidance.</li></ul>Big Bear.ai Holdings, Inc. (BBAI) stock jumped over 12% in Monday’s extended session after the company reported a third-quarter beat and announced an M&amp;A deal, buoying retail sentiment.<a href="https://stocktwits.com/symbol/BBAI">BigBear stock</a> has been on a volatile ride this year en route to its 28% year-to-date gains.&nbsp;<h2 class="st-heading-2">BigBear’s Doubled Down AI Bet</h2>The McLean, Virginia-based artificial intelligence (AI)-powered decision intelligence solutions company said it has signed an agreement to buy Ask Sage for $250 million. Ask Sage is a generative AI (GenAI) platform designed for the secure distribution of AI models and agentic AI capabilities, primarily for defense and national security agencies and other highly regulated sectors.Big Bear noted that Sage already supports more than 100,000 users on 16,000 government teams and across hundreds of commercial companies. Ask Sage is expected to deliver annual recurring revenue (ARR) of approximately $25 million in 2025, nearly six times the amount it recorded in 2024.&nbsp;CEO Kevin McAleenan said, “By integrating Ask Sage with BigBear.ai, we are creating what the market has been asking for: a secure, integrated AI platform that connects software, data, and mission services in one place.” The deal is expected to close in either the fourth quarter of 2025 or the first quarter of 2026.<h2 class="st-heading-2">BigBear’s Q3 Earnings Snapshot</h2>The net loss per share for the fiscal year 2025 fourth quarter narrowed to $0.03 from $0.06 a year ago, and revenue fell 20% year over year (YoY) to $33.1 million. The results, however, exceeded the Fiscal.ai-compiled consensus estimates for a loss of $0.07 and revenue of $31.82 million.The company blamed the YoY revenue drop on lower volume in certain Army programs, and said the narrower net loss is due to non-cash changes in the fair value of the convertible 2029 notes and warrants.&nbsp;Gross margin contracted 350 basis points YoY due to the absence of some high-margin programs that benefited the year-ago quarter.BigBear ended the quarter with a backlog of $376 million.<h2 class="st-heading-2">BigBear’s Outlook</h2>Despite the ongoing government shutdown, the company reaffirmed its 2025 revenue guidance of $125 million to $140 million, which aligns with the consensus estimate of $133.53 million.<h2 class="st-heading-2">What BigBear Retail Feels About Stock After Q3 Print</h2>On Stocktwits, retail sentiment toward the stock shifted to ‘bullish’ as of early Tuesday, from ‘bearish’ a day ago. The 24-hour message volume leading up to late&nbsp; Monday surged up by about 1,500%.<figure class="image"><img style="aspect-ratio:677/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_11_11_at_12_27_52_AM_png_f6bac86ee7.webp" alt="Screenshot 2025-11-11 at 12.27.52 AM.png" width="677" height="58"><figcaption>BBAI sentiment and message volume as of 2:25 a.m. ET, Nov. 11 | source: Stocktwits</figcaption></figure>A bullish watcher said there is a good chance the stock will open above $7 on Tuesday.<stembedurl>https://stocktwits.com/MyEfund/message/635695260</stembedurl>Another user expressed comfort in&nbsp;holding the stock. “I don’t feel as bad holding this stock anymore after today’s earnings call.”<stembedurl>https://stocktwits.com/DARK_SCROOGIE/message/635690861</stembedurl>The average analysts' price target for BigBear stock is $5.83, according to Koyfin, implying roughly 2% upside from Monday's closing price.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intel-hit-by-ai-brain-drain-as-top-execs-depart-for-rivals/cLPdQ7DRE2w">Intel Hit By AI Brain Drain As Top Execs Depart For Rivals: Sachin Katti Joins OpenAI After Saurabh Kulkarni's Jump To AMD</a>

The logo of BigBear.ai Holdings, Inc. displayed on a smartphone screen, with the company's latest stock market chart visible in the background on April 26, 2025, in Chongqing, China. (Photo illustration credit: Cheng Xin/Getty Images)

BigBear Stock Surges Over 12% After-Hours On $250M Ask Sage Deal, Q3 Beat — Retail Impressed With Results

BigBear announced a strategic acquisition of a GenAI platform, which is growing revenue at a scorching pace.

BigBear Stock Surges Over 12% After-Hours On $250M Ask Sage Deal, Q3 Beat

<ul class="summary-bullets"><li>According to Fiscal.ai-compiled consensus, BigBear is expected to report a loss per share of $0.07 and revenue of $31.82 million.</li><li>During the quarter, the company announced several deals, including one that aims to deploy advanced AI and orchestration technologies in support of the U.S. Navy.</li><li>BigBear stock is up about 17.7% YTD.</li></ul>Big Bear.ai Holdings, Inc. (BBAI) stock rallied nearly 4% in premarket trade ahead of the company’s quarterly earnings report, due after the market closes on Monday. The artificial intelligence (AI)-powered decision intelligence solutions firm has attracted attention from retail traders, even as analysts forecast a wider loss and lower revenue compared to last year.For the year-to-date period,&nbsp;<a href="https://stocktwits.com/symbol/BBAI">BigBear stock</a> has gained about 17.7%, underperforming the broader market and the tech sector.<h2 class="st-heading-2">Retail Excited About BigBear’s Q3</h2>When retail users of the Stocktwits platform were asked which earnings report they were most excited for the week of Nov.10, a majority picked BigBear, reflecting interest in the stock. An ongoing poll that has received responses from 11,200 users so far has shown that 30% are excited about BigBear’s earnings. AST SpaceMobile (ASTS), Nebius N.V. (NBIS) and Rocket Lab (RKLB) were mentioned by 25%, 23% and 22% of the respondents, respectively.<a href="https://stocktwits.com/StocktwitsPolls/message/635353734"><img src="https://news.stocktwits-cdn.com/Screenshot_2025_11_10_at_4_37_04_AM_png_a62853f334.webp" alt="Screenshot 2025-11-10 at 4.37.04 AM.png"></a>A Stocktwits user hoped the stock would gain enough momentum to hit double digits before Christmas, based on the view that BigBear's earnings report would not be too bad. Another user stated that the stock is poised to take off and will continue rallying until the end of the year. They set their sights on $12.<stembedurl>https://stocktwits.com/Paul243/message/635557229</stembedurl><stembedurl>https://stocktwits.com/Ohad12/message/635559688</stembedurl>A third user said he would continue to stack the stock.<stembedurl>https://stocktwits.com/marzo34/message/635554283</stembedurl><h2 class="st-heading-2">What Analysts Expect From BigBear’s Q3 Print</h2>According to Fiscal.ai-compiled consensus, BigBear is expected to report a loss per share of $0.07 and revenue of $31.82 million. This compares to the year-ago’s loss per share of $0.05 and revenue of $41.51 million.During the quarter, the company announced several deals, including one that aims to deploy advanced AI and orchestration technologies in support of the U.S. Naval Forces Southern Command. The company also announced a strategic partnership with Tsecond to deliver AI-enabled edge infrastructure for mission-critical operations.The average analysts’ price target for BigBear stock is $5.83, according to Koyfin, implying roughly 2.70% potential upside.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-rumble-stock-is-soaring-nearly-16-in-premarket/cLPcX3hREcH">Why Rumble Stock Is Soaring Nearly 16% In Premarket</a>

In this photo illustration, a person holds a smartphone displaying the logo of BigBear.ai Holdings, Inc. (NYSE: BBAI), on August 8, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

BigBear Retail’s Top Earnings Pick Of The Week Ahead: Stock Gains Nearly 4% Premarket Ahead Of Q3 

BigBear retail is buzzing about the stock taking off and rallying through the year-end.

IWC
iShares Micro-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWC News

IWCiShares Micro-Cap ETF